StockNews.AISignal intelligence
Company intelligence

NVS

Novartis AG · NYSE · Healthcare

Price$160.50+0.16% · +$0.25
Market cap303.12BEquity value
P / E18.5Trailing ratio
Volume1.4MLatest session
Market data

NVS price chart

TradingView
Related signals
1 min delayed

Browse public NVS signals with their source context and measured market impact. Open any signal for its permanent analysis page.

NVSNov 2, 2026-0.50% since signal

Novartis Heart-Drug Trial Failure Prompts Reassessment of Cardiovascular Pipeline

Novartis disclosed the failure of its experimental heart drug in a large clinical trial, undermining expectations for a potential cardiovascular breakthrough. The setback could depress near-term valuation of the company’s cardiovascular portfolio and raise questions about development strategy and timelines. Investors will likely scrutinize follow-up data and management commentary for clarity on next steps.

View signal analysis
NVSOct 27, 2026+1.98% since signal

Novartis lifts full-year guidance on robust Q3 demand for cancer and MS drugs

Novartis raised its full-year core operating income guidance after stronger-than-expected demand in Q3 for its cancer and multiple sclerosis medicines. The update underscores resilience and pricing power for its oncology/MS portfolio, potentially boosting near-term shares and valuation. Investors should monitor quarterly execution, product uptake, and potential pricing/regulatory risks that could temper the upside.

View signal analysis
NVSOct 7, 2026-0.32% since signal

FDA expands Novartis CSU drug label, boosting near-term TAM

The FDA expanded approval for Novartis' chronic spontaneous urticaria treatment to include adults, expanding the drug's addressable market. While the company did not disclose any revenue figures, the change could lift near-term demand if physicians adopt the therapy and payers provide coverage. The development adds a positive regulatory catalyst to NVS's dermatology portfolio.

View signal analysis
NVSOct 2, 2026-0.04% since signal

Novartis inks $7.8 billion RNA therapy licensing deal with Abogen

Novartis' licensing agreement with Abogen, valued at about $7.8 billion, aims to advance RNA-based therapy. The announcement signals a strategic expansion of the company's RNA portfolio and potential future milestones, though specifics on upfront payments or timing were not disclosed. If realized, the deal could augment Novartis' long-term pipeline value and regional collaboration footprint.

View signal analysis
Research

Company intelligence